Trials / Completed
CompletedNCT00190762
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma. Given this, it is hypothesized that Pemetrexed may be active in second-line mesothelioma in which the standard treatment is best supportive care. This study will compare survival of previously treated patients with malignant pleural mesothelioma who receive Pemetrexed plus best supportive care to the survival of similar patients who receive best supportive care alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed |
Timeline
- Start date
- 2001-10-01
- Completion
- 2005-11-01
- First posted
- 2005-09-19
- Last updated
- 2007-01-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00190762. Inclusion in this directory is not an endorsement.